What Desmopressin Teva Treats: Main Uses and Benefits

This therapeutic agent is commonly used to help with symptoms related to systemic imbalance. It is applied in contexts where pronounced symptoms include the constant production of abnormally large volumes of urine (Polyuria) and the resulting severe, chronic thirst (Polydipsia). The medication supports the process of maintaining fluid stability and assists with easing the discomfort and functional strain associated with these intense fluid loss manifestations.

---

This medication is used to address symptoms related to conditions involving fluid imbalance, nocturnal voiding concerns, and specific mild bleeding tendencies.

“It contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.”

Desmopressin Teva is commonly used to support patients experiencing disruptive urinary patterns during sleep. This application contributes to improved sleep quality and offers symptomatic relief that helps patients cope more steadily with these distressing, sleep-interrupting episodes. It is considered relevant in the management of specific mild bleeding tendencies, providing support that helps ease the overall symptom burden associated with these conditions.

---

Quick Fact: Relief for Excessive Diuresis

This medication plays a role in managing the symptoms of fluid imbalance, helping reduce urine volume and easing the constant demand of thirst often seen in patients with Central Diabetes Insipidus.

Eligibility Map: Who can and cannot use Desmopressin Teva — Official Regulatory Information

The eligibility profile for Desmopressin Teva is strictly defined by regulatory authorities to manage the risks associated with fluid retention and hyponatremia (low sodium levels).

---

Eligibility Scope

Classification	Eligibility Rules
Populations for Whom Use is Allowed	Adults and children (typically 5 years) with central diabetes insipidus, primary nocturnal enuresis (PNE), or nocturia.
Populations for Whom Use is Contraindicated	Individuals with moderate to severe renal impairment (creatinine clearance < 50 mL/ min), known or suspected cardiac insufficiency (heart failure), known hyponatremia, habitual or psychogenic polydipsia, or those treated chronically with diuretic agents.

---

Age-Related and Condition-Specific Restrictions

Official labeling defines specific restrictions based on age and organ function:

• Pediatric Use: The medicine is approved for use in children 5 years of age for PNE, but the minimum age may vary by formulation and region.
• Geriatric Use: Initiation of treatment for nocturia or PNE is not recommended in patients 65 years of age and older due to an increased risk of hyponatremia.
• Pregnancy and Lactation: Use during pregnancy is generally restricted and should occur only if clearly needed. It can be used while breastfeeding as the transferred amount is clinically insignificant.

These constraints ensure the medicine is only used by populations that can safely manage its effects on fluid balance.

The interaction profile of Desmopressin Teva is primarily defined by the risk of hyponatremia (low blood sodium) resulting from its documented water-retaining effect.

---

Contraindicated Combinations

Co-administration with certain medications is strictly prohibited as official regulatory documents state it significantly increases the risk of severe hyponatremia. This includes Loop Diuretics and both Systemic and Inhaled Glucocorticoids.

---

Increased Risk of Hyponatremia (Pharmacodynamic)

Official labeling documents confirm that co-administration with other medicines that cause water retention requires more frequent monitoring of serum sodium. This additive, pharmacodynamic potentiation is documented with substance classes such as Tricyclic Antidepressants (TCAs), Selective Serotonin Re-uptake Inhibitors (SSRIs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and specific agents including Carbamazepine, Chlorpromazine, and certain Opiate Analgesics.

---

Exposure Effects and Substance Restrictions

The concurrent use of Loperamide has been officially shown to increase desmopressin plasma concentrations three-fold, enhancing the risk of water retention. Conversely, the ingestion of a standardized meal results in a significant decrease in desmopressin bioavailability. To mitigate risk, fluid intake must be strictly limited from one hour before administration until eight hours after, and both alcohol and caffeine must be avoided before bedtime.

---

Population Considerations

For patients 65 years of age or older, more frequent monitoring of serum sodium is explicitly recommended when they are receiving concomitant medications that increase the risk of hyponatremia.

Desmopressin Teva, a synthetic analog of arginine vasopressin, functions as a highly selective agonist primarily targeting the Vasopressin 2 (V2) receptors. These Gs-protein coupled receptors are localized on the basolateral membrane of the principal cells within the renal collecting ducts and on vascular endothelial cells.

Binding to the V2 receptor initiates a molecular pathway involving the activation of adenylyl cyclase. This enzyme catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP), leading to an intracellular rise in cAMP concentration. The elevated cAMP levels subsequently activate Protein Kinase A (PKA).

In renal collecting duct cells, PKA-mediated phosphorylation triggers the translocation and insertion of Aquaporin-2 (AQP2) water channels from the cytoplasm into the apical membrane. This action increases the hydraulic permeability of the collecting duct epithelium, promoting the passive reabsorption of water from the tubular lumen back into the systemic circulation. This results in a system-level physiological consequence of reduced renal water excretion and increased urine osmolality.

Concurrently, in vascular endothelial cells, V2 receptor agonism similarly increases intracellular cAMP, which facilitates the exocytosis of storage granules, specifically the Weibel-Palade bodies. This cellular release mechanism modulates systemic protein levels by promoting the secretion of stored von Willebrand factor (VWF) and Coagulation Factor VIII (FVIII) into the plasma compartment.

The use of desmopressin is governed by specific instructions, and administration is highly dependent on the chosen dosage form and indication. The medicine is available via oral tablets, the rapidly dissolving oral lyophilisate (sublingual), intranasal spray, and solution for injection for intravenous (IV) or subcutaneous (SUBQ) administration.

The initial dosage is individually titrated for each patient, starting with defined minimums. For example, the oral dose for Central Diabetes Insipidus (DI) typically starts at 0.05 mg to 0.1 mg once or twice daily, adjusting within a wide range up to a total daily maximum of 1.2 mg. For Primary Nocturnal Enuresis, the starting oral tablet dose is 0.2 mg once daily at bedtime, with therapy needing reassessment after 3 months.

A mandatory fluid restriction protocol must be observed by all patients receiving the drug for its antidiuretic effect. Fluid intake must be strictly limited, usually from one hour before the dose until the next morning, as a condition for proper use. Form-specific procedural steps are required: the IV injection for hemostatic use must be diluted in 0.9% Sodium Chloride and administered as a slow infusion over 15 to 30 minutes, while the oral lyophilisate must be placed under the tongue to dissolve without water. Special caution and potential dose adjustments are required for older adults and those with impaired kidney function. Switching between dosage forms necessitates a new individual dose titration due to significant differences in bioavailability.

Desmopressin Teva: Recent Clinical Evidence

Desmopressin Teva is a formulation of desmopressin acetate, a synthetic analog of the naturally occurring antidiuretic hormone (ADH) vasopressin. Its mechanism of action involves mimicking ADH to promote water reabsorption in the kidneys, which helps to reduce the volume of urine produced. The research for this specific generic formulation focuses on establishing its bioequivalence to the originator product.

Bioequivalence and Formulation

As a generic medicinal product, Desmopressin Teva underwent studies to confirm it delivers the active substance (desmopressin) into the bloodstream at the same rate and extent as the reference product. This is known as bioequivalence. These studies are typically conducted using healthy volunteers. Upon confirmation of bioequivalence, no new pre-clinical or clinical studies related to efficacy are usually required.

Clinical Efficacy Research

The established efficacy of desmopressin, as demonstrated by the original clinical development program and subsequent research, relates primarily to its use in conditions involving water imbalance or deficient ADH production, such as:

• Nocturia (excessive nighttime urination) due to nocturnal polyuria in adults.
• Central Diabetes Insipidus (a condition that causes excessive thirst and urination).
• Primary Nocturnal Enuresis (bedwetting) in children and adolescents.

Randomized controlled trials (RCTs) involving desmopressin have explored its effect on reducing the mean number of nocturnal voids and increasing the duration of the first period of undisturbed sleep compared to placebo. One double-blind study involving men with nocturia reported a reduction in nocturnal voids from 3.0 to 1.7 and an increase in the first sleep period from 2.7 to 4.5 hours in the desmopressin group.

Safety and Research Context

While studies examine the side effect profile, hyponatremia (low sodium levels in the blood) remains a central consideration in clinical research, particularly when the drug is used in older adults. Research protocols often establish specific exclusion criteria for participants with conditions like uncontrolled hypertension, heart failure, or pre-existing kidney impairment to manage the risk of fluid retention.

Key Studies & References

1. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Desmopressine-acetaat 0,1 TEVA, 0.1 mg tablets Des
2. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis

Common questions about Desmopressin Teva (FAQ)

Q: Is Desmopressin Teva available in different forms, like a tablet or spray?

A: Official regulatory documents describe desmopressin as being available in multiple product forms. These include oral tablets, an oral lyophilisate (a fast-dissolving tablet placed under the tongue), an intranasal spray, and solutions for injection.

Q: Is Desmopressin Teva the same as other forms of desmopressin?

A: Desmopressin Teva is one manufacturer’s product that contains the active ingredient desmopressin. This active ingredient is the same medication found in other versions of desmopressin and is described as a synthetic analog of the natural hormone vasopressin.

Q: Why is Desmopressin Teva sometimes called a synthetic hormone?

A: Official regulatory descriptions refer to desmopressin as a synthetic analog of the natural pituitary hormone vasopressin (also known as ADH). This indicates it is an artificially made chemical designed to mimic the action of the hormone already produced by the body.

Q: How quickly should I expect Desmopressin Teva to start working?

A: According to official product information, the onset of the antidiuretic effect is generally described as occurring quickly, often within 30 to 60 minutes after administration. The precise onset time may vary depending on the specific product form and individual patient factors.

Q: How long does the effect of one dose of Desmopressin Teva usually last?

A: The duration of the antidiuretic effect (the effect that reduces urine production) is described in official sources as lasting approximately 6 to 14 hours. This stated duration is dependent on the route of administration and is subject to individual patient response.

Q: Are there any common foods or drinks that should be limited while using Desmopressin Teva?

A: Regulatory documents state that fluid intake must be strictly limited for a specific period around dosing. Additionally, official warnings specifically mention avoiding alcohol and caffeine before bedtime when the medication is used for nocturnal conditions.

Q: Is Desmopressin Teva safe to use for older people (seniors)?

A: Official labeling indicates that patients 65 years of age or older should be monitored carefully. This includes more frequent checks of serum sodium levels due to an increased risk of hyponatremia (low sodium in the blood) documented in this population.

Q: Why is it important to check sodium levels when using Desmopressin Teva?

A: Monitoring serum sodium is a regulatory requirement because the drug’s intended action is to retain water in the body. This water-retaining effect can dilute the sodium in the blood, potentially leading to a dangerous condition called hyponatremia (low blood sodium).

Q: Can taking Desmopressin Teva affect the results of other medical tests?

A: The injection form of desmopressin is described in official documents as increasing the plasma levels of von Willebrand factor (VWF) and Coagulation Factor VIII (FVIII). These factors are measured in certain blood tests related to clotting.

Q: Is it common to feel thirsty when starting Desmopressin Teva?

A: Official safety information includes increased thirst among the less common side effects reported by patients. Persistent or severe thirst can also be a symptom of hyponatremia and is a concern documented in the official safety information.

Q: What is 'hyponatremia' and how does it relate to Desmopressin Teva?

A: Hyponatremia is defined in regulatory warnings as having a low level of sodium in the blood. Desmopressin works by causing the kidneys to retain water, which can dilute the body’s sodium concentration and result in this condition.

Q: Does Desmopressin Teva affect blood pressure?

A: Official documents state that desmopressin may cause either hypotension (low blood pressure) or hypertension (high blood pressure). Its use is subject to specific regulatory restrictions in patients with uncontrolled high blood pressure.

Q: Can Desmopressin Teva be taken if I have kidney problems?

A: Official labeling states that desmopressin is contraindicated (should not be used) in patients with moderate to severe renal impairment (a specific level of impaired kidney function). Official product information emphasizes monitoring of kidney function for patients using this medication.

Q: Does Desmopressin Teva cause weight changes?

A: Unexplained weight gain is listed in the official safety information as a rare symptom documented to be associated with fluid retention or hyponatremia. Fluid retention can cause an increase in body weight.

Q: Is it possible for Desmopressin Teva to cause headaches?

A: Headache is listed as one of the commonly reported side effects in the official safety information. A severe or prolonged headache is a symptom that may be associated with hyponatremia, according to regulatory documents.

Q: Can children be prescribed Desmopressin Teva for nocturnal enuresis?

A: Official consumer information for the Teva tablet version states it is prescribed for children 5 years of age and older who wet their bed at night. This use is documented in official labeling for children in this age group.

Q: What happens if I stop using Desmopressin Teva suddenly?

A: Official regulatory documents describe a gradual cessation (tapering) of the medication for certain conditions like Primary Nocturnal Enuresis. This is done to reduce the risk of the condition returning.

Q: Is Desmopressin Teva typically used for short-term or long-term management?

A: Desmopressin may be used for long-term management of chronic conditions like Diabetes Insipidus. For conditions like Primary Nocturnal Enuresis, official labeling recommends therapy reassessment after 3 months to determine the need for continuation.

Q: What are the major side effects listed in the official safety information for Desmopressin Teva?

A: Major side effects listed in official safety information include hyponatremia (low blood sodium), headache, nausea, nasal congestion (with the spray form), and signs of fluid retention.

Q: Is Desmopressin Teva considered a scheduled or controlled drug?

A: Desmopressin is not classified as a controlled substance in the United States. Controlled substances are medications that have a recognized potential for abuse or dependence.

Q: What is the research evidence for using Desmopressin Teva for its approved uses?

A: Official regulatory approval is based on clinical studies that examine its effect on reducing urine volume and increasing urine osmolality. This includes studies for conditions like Diabetes Insipidus and Primary Nocturnal Enuresis.

Q: Are there specific warnings about driving or operating machinery while taking Desmopressin Teva?

A: Official labeling warns that side effects such as dizziness, confusion, or headache are associated with the use of desmopressin. Regulatory documents indicate that these effects may impact an individual's ability to drive or operate machinery.

Q: Does Desmopressin Teva have any potential effects on mood or sleep?

A: Official safety information includes psychiatric side effects such as restlessness, confusion, and abnormal thoughts. These symptoms are documented as adverse reactions associated with the medication's use.

Q: How is the safety of Desmopressin Teva monitored after it is released to the public?

A: Like all medications, the safety of desmopressin is continuously monitored through regulatory post-marketing surveillance. This involves the ongoing collection and reporting of adverse events by patients and healthcare professionals.

Q: Is Desmopressin Teva used to manage conditions other than excessive urination?

A: Yes, the injection form of desmopressin is also indicated in official regulatory documents for the management of certain bleeding disorders. This is due to its effect on increasing the levels of certain clotting factors.

Q: Do you have to take Desmopressin Teva at a specific time of day?

A: For approved uses like Primary Nocturnal Enuresis and Nocturia, official instructions specify taking the dose once daily at bedtime or 1 hour before bedtime.

Q: Is Desmopressin Teva ever prescribed for bleeding disorders?

A: Yes, the injection form of desmopressin is indicated in official regulatory documents for the management of certain bleeding disorders, such as mild Hemophilia A and Type I von Willebrand’s disease.

Q: Are there any known issues with Desmopressin Teva and pregnancy or breastfeeding?

A: Official labeling describes risk summaries for these situations. The regulatory documents emphasize that potential benefits and risks in these populations are considered.

Q: Is Desmopressin Teva a steroid?

A: No, official regulatory documents classify desmopressin as a synthetic vasopressin analog. This means it is a drug that mimics the action of a natural hormone, but it is not classified as a steroid.

Q: What is the standard regulatory information for Desmopressin Teva?

A: The information that governs its use is overseen and published by government agencies such as the U.S. FDA, Health Canada, and the EMA (European Medicines Agency). This information is compiled into official product labeling and summaries.

Q: How is Desmopressin Teva different from medicines that treat an overactive bladder?

A: Desmopressin is described as working by acting on the kidneys to reduce the amount of urine produced. Medicines for overactive bladder typically work differently by affecting the muscles and nerves of the bladder itself.

Q: What are the possible long-term safety considerations for Desmopressin Teva?

A: For long-term use, particularly for chronic conditions like Diabetes Insipidus, official labeling emphasizes the need for ongoing, periodic monitoring of serum sodium levels and kidney function to mitigate risks documented in regulatory data.

Q: Why do some people experience dry mouth with Desmopressin Teva?

A: Dry mouth is listed as one of the commonly reported side effects in the official safety information for the oral forms of desmopressin.

Q: Is Desmopressin Teva covered by official regulatory body guidelines?

A: Yes, the use and safety of desmopressin are governed by product guidelines and official labeling documents published by government authorities, such as the U.S. FDA and Health Canada.

The official storage and disposal requirements for Desmopressin Teva are strictly defined by regulatory documents and differ by dosage form.

Storage Requirements by Formulation

Dosage Form	Mandatory Storage Condition	In-Use Stability Constraint
Nasal Solution	Refrigerated: 2 C to 8 C (36 F to 46 F).	Discard after 50 doses. Stable for up to 3 weeks if stored temporarily below 25 C.
Oral Lyophilisate	Below 25 C (77 F) in the original, tightly closed container.	Protect from moisture and light; container desiccants must remain.
Oral Tablets	Store at room temperature.	Keep away from heat, moisture, and direct light. Must be kept from freezing.

All Desmopressin forms must be stored in their original, tightly closed container and kept out of the sight and reach of children. Unused or expired medicine must not be kept and should be disposed of in accordance with local, state, or national regulations, often requiring consultation with a pharmacist.